Predictors of real-world utilisation of docetaxel combined with androgen deprivation therapy in metastatic hormone-sensitive prostate cancer

被引:10
作者
Azad, Arun A. [1 ,3 ,4 ]
Tran, Ben [1 ,7 ]
Davis, Ian D. [5 ,8 ]
Parente, Phillip [5 ,8 ]
Evans, Melanie [6 ]
Wong, Shirley [9 ]
Brown, Stephen [13 ]
Evans, Sue [10 ]
Millar, Jeremy [11 ,12 ]
Murphy, Declan G. [2 ,3 ]
Papa, Nathan [6 ]
机构
[1] Peter MacCallum Canc Ctr, Dept Med Oncol, Melbourne, Vic, Australia
[2] Peter MacCallum Canc Ctr, Div Canc Surg, Melbourne, Vic, Australia
[3] Univ Melbourne, Sir Peter MacCallum Dept Oncol, Melbourne, Vic, Australia
[4] Monash Univ, Sch Clin Sci, Melbourne, Vic, Australia
[5] Monash Univ, Eastern Hlth Clin Sch, Melbourne, Vic, Australia
[6] Monash Univ, Sch Publ Hlth & Prevent Med, Melbourne, Vic, Australia
[7] Eastern Hlth, Walter & Eliza Hall Inst, Div Personalised Oncol, Melbourne, Vic, Australia
[8] Eastern Hlth, Med Oncol Unit, Melbourne, Vic, Australia
[9] Western Hlth, Canc Serv, Melbourne, Vic, Australia
[10] Canc Council Victoria, Victorian Canc Registry, Melbourne, Vic, Australia
[11] Alfred Hosp, Alfred Hlth Radiat Oncol, Melbourne, Vic, Australia
[12] Monash Univ, Alfred Ctr, Cent Clin Sch, Melbourne, Vic, Australia
[13] Ballarat Reg Integrated Canc Ctr, Med Oncol, Ballarat, Vic, Australia
关键词
prostate cancer; chemotherapy; docetaxel; castration; hormone-sensitive; metastatic; MEN;
D O I
10.1111/imj.15288
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background Docetaxel has emerged as a standard-of-care for metastatic hormone-sensitive prostate cancer (mHSPC). Uptake of docetaxel for mHSPC in Australia has not previously been reported. Aims To investigate the real-world uptake of docetaxel in mHSPC and to identify predictors of utilisation of docetaxel in mHSPC. Methods Men diagnosed from June 2014 to December 2018 and enrolled in the Prostate Cancer Outcomes Registry-Victoria (PCOR-Vic) were included. Data collected include demographics, diagnosis method and institution, staging investigations and treatments within 12 months of diagnosis. Wilcoxon rank-sum, Chi-squared and trend tests were used to identify predictors of docetaxel utilisation. All predictors were entered as covariates simultaneously into a multivariable logistic regression model. Statistical significance was set at 0.05 (two sided). Results In all, 1014 men with mHSPC were analysed, 25% of whom received docetaxel with androgen deprivation therapy. Uptake of docetaxel increased from 20% in 2014 to 33% in 2018. Predictors of higher usage of docetaxel were younger age and treatment in a private hospital, with both remaining significant on multivariable analysis. Notably, the proportion of men aged <70 years receiving docetaxel increased from 54% in 2014-2015 to 64% in 2016-2018, while in men aged >= 70 years the comparative figures were 15% and 22% respectively. Conclusions Although docetaxel was not used in the majority of cases, there was a clear increase in docetaxel uptake, especially in younger men following publication of the CHAARTED and STAMPEDE trials. Identifying barriers to real-world implementation of pivotal clinical trial data is critical to improving outcomes in mHSPC.
引用
收藏
页码:1339 / 1346
页数:8
相关论文
共 21 条
[1]   Not all prostate cancer is the same - patient perceptions: an Asia-Pacific region study [J].
Akakura, Koichiro ;
Bolton, Damien ;
Grillo, Vince ;
Mermod, Naomi .
BJU INTERNATIONAL, 2020, 126 :38-45
[2]  
[Anonymous], 2020, NATL PROSTATE CANC A
[3]   Management of patients with advanced prostate cancer in the Asia Pacific region: "real-world' consideration of results from the Advanced Prostate Cancer Consensus Conference (APCCC) 2017 [J].
Chiong, Edmund ;
Murphy, Declan G. ;
Akaza, Hideyuki ;
Buchan, Nicholas C. ;
Chung, Byung Ha ;
Kanesvaran, Ravindran ;
Khochikar, Makarand ;
Letran, Jason ;
Lojanapiwat, Bannakij ;
Ng, Chi-fai ;
Ong, Teng ;
Pu, Yeong-Shiau ;
Saad, Marniza ;
Schubach, Kathryn ;
Turkeri, Levent ;
Umbas, Rainy ;
Vu Le Chuyen ;
Williams, Scott ;
Ye, Ding-Wei ;
Davis, Ian D. .
BJU INTERNATIONAL, 2019, 123 (01) :22-34
[4]  
Clarke NW, 2019, ANN ONCOL, V30, P1992, DOI [10.1016/j.annonc.2020.01.002, 10.1093/annonc/mdz396]
[5]   Chemotherapy at First Diagnosis of Advanced Prostate Cancer - Revolution or Evolution? Findings from a British Uro-oncology Group UK Survey to Evaluate Oncologists' Views on First-line Docetaxel in Combination with Androgen Deprivation Therapy in Castrate-sensitive Metastatic and High-risk/Locally Advanced Prostate Cancer [J].
Davda, R. ;
Hughes, S. ;
Jones, R. ;
Crabb, S. J. ;
Troup, J. ;
Payne, H. .
CLINICAL ONCOLOGY, 2016, 28 (06) :376-385
[6]   The Prostate Cancer Registry: monitoring patterns and quality of care for men diagnosed with prostate cancer [J].
Evans, Sue M. ;
Millar, Jeremy L. ;
Wood, Julie M. ;
Davis, Ian D. ;
Bolton, Damien ;
Giles, Graham G. ;
Frydenberg, Mark ;
Frauman, Albert ;
Costello, Antony ;
McNeil, John J. .
BJU INTERNATIONAL, 2013, 111 (4B) :E158-E166
[7]   Time of metastatic disease presentation and volume of disease are prognostic for metastatic hormone sensitive prostate cancer (mHSPC) [J].
Francini, Edoardo ;
Gray, Kathryn P. ;
Xie, Wanling ;
Shaw, Grace K. ;
Valenca, Loana ;
Bernard, Brandon ;
Albiges, Laurence ;
Harshman, Lauren C. ;
Kantoff, Philip W. ;
Taplin, Mary-Ellen ;
Sweeney, Cristopher J. .
PROSTATE, 2018, 78 (12) :889-895
[8]   Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trial [J].
Gravis, Gwenaelle ;
Fizazi, Karim ;
Joly, Florence ;
Oudard, Stephane ;
Priou, Franck ;
Esterni, Benjamin ;
Latorzeff, Igor ;
Delva, Remy ;
Krakowski, Ivan ;
Laguerre, Brigitte ;
Rolland, Frederic ;
Theodore, Christine ;
Deplanque, Gael ;
Ferrero, Jean Marc ;
Pouessel, Damien ;
Mourey, Loic ;
Beuzeboc, Philippe ;
Zanetta, Sylvie ;
Habibian, Muriel ;
Berdah, Jean Francois ;
Dauba, Jerome ;
Baciuchka, Marjorie ;
Platini, Christian ;
Linassier, Claude ;
Labourey, Jean Luc ;
Machiels, Jean Pascal ;
El Kouri, Claude ;
Ravaud, Alain ;
Suc, Etienne ;
Eymard, Jean Christophe ;
Hasbini, Ali ;
Bousquet, Guilhem ;
Soulie, Michel .
LANCET ONCOLOGY, 2013, 14 (02) :149-158
[9]   Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study [J].
Hofman, Michael S. ;
Lawrentschuk, Nathan ;
Francis, Roslyn J. ;
Tang, Colin ;
Vela, Ian ;
Thomas, Paul ;
Rutherford, Natalie ;
Martin, Jarad M. ;
Frydenberg, Mark ;
Shakher, Ramdave ;
Wong, Lih-Ming ;
Taubman, Kim ;
Lee, Sze Ting ;
Hsiao, Edward ;
Roach, Paul ;
Nottage, Michelle ;
Kirkwood, Ian ;
Hayne, Dickon ;
Link, Emma ;
Marusic, Petra ;
Matera, Anetta ;
Herschtal, Alan ;
Iravani, Amir ;
Hicks, Rodney J. ;
Williams, Scott ;
Murphy, Declan G. .
LANCET, 2020, 395 (10231) :1208-1216
[10]   Studies on prostate cancer II The effects of castration on advanced carcinoma of the prostate gland [J].
Huggins, C ;
Stevens, RE ;
Hodges, CV .
ARCHIVES OF SURGERY, 1941, 43 (02) :209-223